Search in our News Channels
|
|
Search in our Online Store
|
|
Aegera Therapeutics Initiates Four Phase I/II Clinical Trials for AEG35156 |
|
|
|
03 Oct 2007 |
Aegera Therapeutics announced today the initiation of four new clinical oncology studies for AEG35156, a second generation anti-sense therapeutic targeting the X-Linked Inhibitor of Apoptosis
MONTREAL, Canada | October 2, 2007 | Aegera Therapeutics announced today the initiation of four new clinical oncology studies for AEG35156, a second generation anti-sense therapeutic targeting the X-Linked Inhibitor of Apoptosis (XIAP), a key member of the Inhibitor of Apoptosis protein (IAP) family.
Following completion of several Phase I trials, Aegera has initiated an open-label Phase II study in acute myeloid leukemia (AML) with AEG35156 given in combination with ara-C and idarubicin. This study is being performed at six sites across North America including MD Anderson (Texas), Princess Margaret Hospital (Ontario), Johns Hopkins Medical Center (Maryland), Northwestern Memorial Hospital (Illinois), University of California in Los Angeles (California) and Maisonneuve-Rosemont Hospital (Quebec).
In addition, three other multicenter open-label Phase I/II studies have been initiated with AEG35156 in pancreatic cancer, advanced breast cancer and advanced non-small cell lung cancer. In these studies, AEG35156 will be combined with current standard of care chemotherapeutics. The Phase I arm of these trials will determine the recommended dose of AEG35156 to be used in combination with the respective chemotherapeutic agents. The Phase II arm of each study will evaluate the effects of combining AEG35156 with chemotherapy on the expected response rate in these patient populations.
"The mechanism of action of AEG35156 strongly suggests that it will be effective in combination with chemotherapeutics across a wide spectrum of cancer types," commented Aegera's Chief Executive Officer, Dr. Michael Berendt, "Our initial Phase II studies in AML, pancreatic, breast, and non-small cell lung cancer were chosen based on the preclinical data, our understanding of the relevance of the XIAP target, clinical correlates and the considerable medical need for improved treatment in these cancer types."
"Early clinical evidence indicates that AEG35156 reduces XIAP mRNA and protein levels in some solid tumors and hematologic cancers," stated Dr. Bruce Chabner, Aegera Clinical Advisory Board member. "The biological activity of AEG35156, if it is borne out in these trials, should make cancer cells more susceptible to standard chemotherapeutics."
About AEG35156
Cancer cells acquire multiple mutations that disable their normal response to apoptotic triggers. AEG35156, a second generation anti-sense which targets XIAP, is designed to lower the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemotherapy, without harming healthy cells. Aegera's published data with AEG35156, both in vitro and in vivo, strongly supports this hypothesis, and validates XIAP as a novel drug target for the development of anti-cancer therapeutics. AEG35156 has demonstrated strong efficacy in models of lung, breast, ovarian, colorectal and prostate cancers.
About Aegera Therapeutics Inc.
Aegera Therapeutics is a clinical stage biotechnology company focused on developing drugs that control apoptosis to address major unmet medical needs. Multiple programs are in development to induce apoptosis to kill cancer cells and to prevent apoptosis to save injured neuronal cells:
-- AEG35156 targets the key anti-apoptotic protein XIAP, and is currently in multiple human clinical trials for the treatment of solid tumors and leukemia;
-- LS104 is a novel, non-ATP competitive, small molecule tyrosine kinase inhibitor targeting therapeutically significant kinases including JAK2 and Bcr-Abl;
-- AEG40826 is a potent small molecule that neutralizes the activity of key Inhibitor of Apoptosis Proteins (IAPs), and has begun definitive IND-enabling preclinical toxicology studies as an anti-cancer therapeutic;
-- AEG33773 is a novel, orally bioavailable small molecule developed to treat painful diabetic neuropathy; definitive IND-enabling preclinical toxicology testing has been initiated.
SOURCE: CNW GROUP |
|
For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01
La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L
|
 |
|
|
